Clinical Applications in Inflammatory Conditions Inflammatory Bowel Disease (IBD) Preclinical studies have demonstrated BPC-157's efficacy in experimental models of IBD, including both ulcerative colitis and Crohn's disease
The most extensively studied mechanism involves upregulation of vascular endothelial growth factor (VEGF), which promotes angiogenesis, the formation of new blood vessels at injury sites, providing the vascular supply necessary for accelerated tissue repair
Its small size and molecular structure allow it to interact with a wide array of biological targets
Bpc-157, being smaller at 15 amino acids, tends to concentrate more heavily at injection sites while still providing some systemic benefits
While BPC-157 is not a direct muscle-building peptide, its ability to enhance recovery allows you to train harder and bounce back faster
Thus, it increases circulating growth hormone and IGF-1